COMMUNIQUÉS West-GlobeNewswire

Myriad Genetics Announces Expanded Research Collaboration with AstraZeneca

03/01/2018 - 13:05

SALT LAKE CITY, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN ), a leader in molecular diagnostics and personalized medicine, today announced that AstraZeneca will use the Company’s myChoice ® [...]

VBL Therapeutics Announces the Appointments of Susan Kelley and David Hastings to Its Board of Directors

03/01/2018 - 13:05

Senior pharmaceutical executives with extensive experience in immuno-oncology, drug development, commercializing oncology medications and finance TEL AVIV, Israel, Jan. 03, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics ( [...]

ASLAN Pharmaceuticals Acquires Full Global Commercial Rights for Varlitinib From Array BioPharma

03/01/2018 - 09:00

SINGAPORE, Jan. 03, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the [...]

Dr. Tomas Navratil nommé Head of Development de Nicox

03/01/2018 - 07:31

Communiqué de presse Dr. Tomas Navratil nommé Head of Development de Nicox ....................................... 3 janvier 2018 - diffusion à 7:30 Sophia Antipolis, France Nicox S.A. (Euronext Paris : FR0013018124, [...]

Nicox Appoints Tomas Navratil, Ph.D., as Head of Development

03/01/2018 - 07:30

Press Release Nicox Appoints Tomas Navratil, Ph.D., as Head of Development ................................................ January 3, 2018 - release at 7:30 am Sophia Antipolis, France Nicox SA (Euronext Paris: [...]

Basilea reports start of clinical phase 1 study in collaboration with the U.S. Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma

03/01/2018 - 07:16

Basel, Switzerland, January 03, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the initiation of a phase 1 study conducted under its clinical study agreement with the Adult Brain Tumor Consortium (ABTC) [...]

Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer

03/01/2018 - 07:16

Designation based on Phase III MONALEESA-7 results demonstrating superior efficacy of Kisqali in combination with oral endocrine therapy compared to oral endocrine therapy in pre- or perimenopausal women who received no [...]

Addex and Indivior Sign Strategic Partnership to Accelerate Development of GABAB PAMs as Addiction Treatments

03/01/2018 - 07:01

Addex Receives $5 Million Upfront, Potential Milestones of $330 Million and Tiered Royalties up to Double Digit Addex Receives $4 Million Research Funding over 2 years and Retains Rights to Advance Additional GABAB PAMs [...]

assessURhealth, LLC joins Greenway Health online Marketplace for comprehensive health IT solutions

03/01/2018 - 01:47

Tampa, FL, Jan. 02, 2018 (GLOBE NEWSWIRE) -- assessURhealth, LLC , a leading provider of mental and behavioral health screening software, today announced it has joined the Greenway Health online Marketplace of value- [...]

Tetraphase Pharmaceuticals Appoints Larry Tsai, M.D. to Chief Medical Officer

02/01/2018 - 22:35

WATERTOWN, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH ), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant [...]

Tetraphase Pharmaceuticals Announces Submission of New Drug Application to FDA for Eravacycline for the Treatment of Complicated Intra-Abdominal Infections (cIAI)

02/01/2018 - 22:30

WATERTOWN, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH ), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant [...]

Supernus to Present at the 2018 J.P. Morgan Healthcare Conference

02/01/2018 - 22:15

ROCKVILLE, Md., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN ), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central [...]

Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Lead-In to Phase 3, Global Registrational Trial of FPA144 in Front-Line Advanced Gastric Cancer

02/01/2018 - 22:05

SOUTH SAN FRANCISCO, Calif., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc . (Nasdaq: FPRX ), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today [...]

Envigo to Present at the 36th Annual JPMorgan Conference

02/01/2018 - 22:05

EAST MILLSTONE, N.J., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Envigo , a leading provider of nonclinical contract research services and research models, today announced that Adrian Hardy, Chief Executive Officer, and Patricia [...]

Update on progress in cystic fibrosis programs

02/01/2018 - 22:02

Positive results with FLAMINGO study C1 corrector GLPG2222 as monotherapy in homozygous Class II F508del CF patients Study over-recruited within 5 months in the US and Europe GLPG2222 was well tolerated when dosed once [...]

Opiant Pharmaceuticals Receives Approximately $5.3 Million of Cash from Exercise of Outstanding Warrants

02/01/2018 - 22:01

SANTA MONICA, Calif., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT ), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced [...]

CymaBay Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference

02/01/2018 - 22:01

NEWARK, Calif., Jan. 02, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY ), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high [...]

pSivida to Present at the Annual Biotech Showcase Conference

02/01/2018 - 22:01

WATERTOWN, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ: PSDV ) (ASX:PVA), a leader in the development of sustained release drug delivery products, announced today that Nancy Lurker, President and [...]

Trevena Announces FDA Acceptance for Review of New Drug Application for OLINVO™ (oliceridine) Injection

02/01/2018 - 22:01

CHESTERBROOK, Pa., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN ) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for OLINVO™ ( [...]